The Pfizer-BioNTech vaccine is just 33% protection against COVID omicron, according to a recent research by South Africa’s largesare private health insurance.
The Discover According to the Discovery Health study, full lth study found that full COVID-19 immunisation still provides 70% protection against shose who have had an earlier illness variation, with those infected earlier at increased risk.
People who area long time telyat a ccinated are still protecte. According to a study released Tuesday, the ainst serious illness, according to a South African research published Tuesday.
The variation, believed to have developed this fall in southern Africa, appears certain to follow in the footsteps of delta. COVID omicron causes 90% of COVID South Africa and is spreading to Europe. However, the delta form still dominates the American epidemic.
Informationas the out omicron’s properties, including how infectious and harmful it may be, is still emerging.
The recent study by Discovery Health, South Africa’s largest private health insurance, demonstrates that two doses of the Pfizer-BioNTech vaccine only give 33% protection against omicron infection.
It appears that full immunisa—n provides 70% protection against serious illnbe—issgh-risk groups, while it declines slightly in those over 60 and significantly more in those over 70.
“70% is a dropdown. Not wonderful, “said he When it was delta variant, it was 95% effective severe illness; after six months, it was 85% virus,tive severe disease.
It’s unclear if such figures will hold when more omicron patients are evaluated, he added. “It’s all so new.”
